LabGenius is at the forefront of revolutionizing the drug discovery process through the integration of human and machine intelligence, specifically focusing on the development of next-generation therapeutic antibodies. Their innovative platform, known as EVA™, employs a smart robotic system that not only designs and conducts experiments but also learns from them, significantly enhancing the efficiency of antibody discovery. By utilizing an active learning approach called Multi-Objective Bayesian Optimisation (MOBO), LabGenius can navigate complex antibody design spaces more effectively than traditional methods, allowing for the simultaneous optimization of multiple properties. This technology minimizes human bias and increases the likelihood of identifying high-performing antibodies with unique designs that may not be discovered through conventional rational design techniques.

The applications of LabGenius's technology are primarily aimed at the rapid discovery and optimization of novel therapeutic antibodies for treating cancer and inflammatory diseases. Their platform enables the design and testing of extensive panels of multispecific antibodies in a fraction of the time typically required, with the capability to evaluate thousands of novel designs quickly. By tightly integrating experimental workflows with advanced machine learning, LabGenius can explore vast areas of antibody design space, leading to the identification of diverse and high-performing candidates. This innovative approach not only accelerates the drug discovery process but also holds the potential to significantly improve patient outcomes through the development of more effective immunotherapeutics.

United Kingdom

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics.

Cancer

Inflammatory disorders

201.3 Building B, Biscuit Factory, 100 Drummond Road, London SE16 4DG, England, United Kingdom

LabGenius

Company Details